Department of Hepatobiliary and Transplantation Surgery, Freeman Hospital, Newcastle upon Tyne, UK.
Dig Surg. 2013;30(4-6):293-301. doi: 10.1159/000354310. Epub 2013 Aug 21.
A variety of factors have been identified in the literature which influence survival following resection of colorectal liver metastases (CRLM). Much of this literature is historical, and its relevance to contemporary practice is not known. The aim of this study was to identify those factors which influence survival during the era of preoperative chemotherapy in patients undergoing resection of CRLM in a UK centre.
All patients having liver resection for CRLM during an 11-year period up to 2011 were identified from a prospectively maintained database. Prognostic factors analysed included tumour size (≥5 or <5 cm), lymph node status of the primary tumour, margin positivity (R1; <1 mm), neo-adjuvant chemotherapy (for liver), tumour differentiation, number of liver metastases (≥4), preoperative carcinoembryonic antigen (CEA; ≥200 ng/ml) and whether metastases were synchronous (i.e. diagnosed within 12 months of colorectal resection) or metachronous to the primary tumour. Overall survival (OS) was compared using Kaplan-Meier plots and a log rank test for significance. Multivariate analysis was performed using a Cox regression model. Statistical analysis was performed in SPSS v19, and p < 0.05 was considered to be significant.
432 patients underwent resection of CRLM during this period (67% male; mean age 64.5 years), and of these, 54 (13.5%) had re-resections. The overall 5-year survival in this series was 43% with an actuarial 10-year survival of 40%. A preoperative CEA ≥200 ng/ml was present in 10% of patients and was associated with a poorer 5-year OS (24 vs. 45%; p < 0.001). A positive resection margin <1 mm was present in 16% of patients, and this had a negative impact on 5-year OS (15 vs. 47%; p < 0.001). Tumour differentiation, number, biliary or vascular invasion, size, relationship to primary disease, nodal status of the primary disease or the use of neo-adjuvant chemotherapy had no impact on OS. Multivariate analysis identified only the presence of a positive resection margin (OR 1.75; p < 0.05) and a preoperative CEA ≥200 ng/ml (OR 1.88; p < 0.01) as independent predictors of poor OS.
Despite the wide variety of prognostic factors reported in the literature, this study was only able to identify a preoperative CEA ≥200 ng/ml and the presence of tumour within 1 mm of the resection margin as being of value in predicting survival. These variables are likely to identify patients who may benefit from intensive follow-up to enable early aggressive treatment of recurrent disease.
文献中已经确定了多种影响结直肠肝转移(CRLM)切除后生存的因素。其中许多文献都是历史文献,其与当代实践的相关性尚不清楚。本研究的目的是确定在英国中心接受 CRLM 切除术的患者中,在术前化疗时代影响生存的因素。
从一个前瞻性维护的数据库中确定了 11 年内(截至 2011 年)所有因 CRLM 而行肝切除术的患者。分析的预后因素包括肿瘤大小(≥5 或<5 cm)、原发肿瘤的淋巴结状态、切缘阳性(R1;<1 mm)、新辅助化疗(肝)、肿瘤分化、肝转移灶数量(≥4)、术前癌胚抗原(CEA;≥200ng/ml)以及转移灶是否同步(即结直肠切除后 12 个月内诊断)或异时(原发肿瘤)。使用 Kaplan-Meier 图和对数秩检验比较总生存率(OS)的差异,并进行显著性检验。使用 Cox 回归模型进行多变量分析。使用 SPSS v19 进行统计分析,p<0.05 被认为具有统计学意义。
在此期间,有 432 例患者接受了 CRLM 切除术(67%为男性;平均年龄 64.5 岁),其中 54 例(13.5%)进行了再次切除术。本系列的总体 5 年生存率为 43%,10 年生存率为 40%。该系列中有 10%的患者术前 CEA≥200ng/ml,其 5 年 OS 较差(24% vs. 45%;p<0.001)。16%的患者切缘阳性<1mm,这对 5 年 OS 有负面影响(15% vs. 47%;p<0.001)。肿瘤分化程度、数量、胆道或血管侵犯、大小、与原发疾病的关系、原发疾病的淋巴结状态或新辅助化疗的使用对 OS 没有影响。多变量分析仅发现阳性切缘(OR 1.75;p<0.05)和术前 CEA≥200ng/ml(OR 1.88;p<0.01)是 OS 不良的独立预测因素。
尽管文献中报告了广泛的预后因素,但本研究仅能确定术前 CEA≥200ng/ml 和肿瘤距离切缘<1mm 是预测生存的有价值因素。这些变量可能可以识别出可能受益于强化随访以早期积极治疗复发性疾病的患者。